AEON Biopharma, Inc. current report, 28 June 2023

Full document

Business Context and Reporting Period

Priveterra Acquisition Corp. filed this Form 8-K on June 28, 2023, regarding its proposed business combination with AEON Biopharma, Inc. The filing supplements the definitive proxy statement filed May 12, 2023. Priveterra, rather than AEON Biopharma, is the registrant named in the filing.

Key Financial Metrics

This filing is a procedural and proxy-related report. It does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.

Material Changes

  • The special meeting originally scheduled for June 28, 2023, was adjourned to June 30, 2023, at 4:00 p.m. Eastern Time.
  • The adjournment was intended to allow additional time for Priveterra to engage with stockholders.
  • The business combination proposal involving AEON Biopharma remains subject to stockholder consideration and approval.
  • The location, record date, redemption deadline, and other proposals were unchanged.
  • Stockholders who previously submitted proxies and do not wish to change their votes need not take further action. Eligible stockholders may withdraw redemption requests before the rescheduled meeting by requesting return of their shares from the transfer agent.

Guidance, Outlook, Risks, and Unusual Items

  • No financial guidance or operating outlook is provided.
  • The filing contains customary forward-looking statement disclosures, noting that the proposed transaction and related expectations are subject to risks and uncertainties.
  • Investors are directed to the definitive proxy statement, related S-4 registration statement, and other SEC filings for risk factors and information regarding the transaction, solicitation participants, and their interests.
  • The unusual item reported is the adjournment of the special meeting and the related proxy supplement.

Important Facts to Verify

  • Whether stockholders approved the business combination at the rescheduled June 30, 2023 meeting.
  • The number of shares redeemed and the resulting cash available to the combined company.
  • The final transaction terms, financing arrangements, and capitalization following closing.
  • Any subsequent SEC filings reporting completion, amendment, termination, or delay of the AEON Biopharma transaction.
  • AEON Biopharma’s underlying financial performance and liquidity, which are not included in this Form 8-K.